A Global Leader in Meaningful, Industry-leading Solutions for Chronic Pain and Neurological Diseases

Pain relief made personal

Pain relief made personal

There is no one-size-fits-all treatment for pain and neurological diseases, such as Parkinson’s Disease. Each patient’s needs are unique and personal, which is why physicians need customizable treatment solutions. At Boston Scientific, we’re dedicated to working closely with both physicians and patients to develop meaningful, industry-leading solutions that can improve the quality of life for millions worldwide.

Advancing Deep Brain Stimulation. Because Parkinson’s disease is progressive, it’s critical to provide therapy that evolves with the patient. The Vercise™ Primary Cell (PC) and Vercise Gevia™ Deep Brain Stimulation (DBS) Systems leverage the Vercise Cartesia™ Directional Lead to control the symptoms of Parkinson’s disease through highly personalized therapy. Eight individually controlled electrodes on each lead allow physicians to adjust the range, shape, position and direction of electrical stimulation, which can reduce unwanted side effects and be adapted for continued symptom relief as Parkinson’s disease progresses.

Personalizing Pain Therapy. Each patient experiences pain differently. That’s why we designed the Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System to provide personalized, long-lasting pain relief. With the ability to provide multiple therapies in one device, patients and their physicians can easily find the therapy that works best for them.

Setting the Standard.  The Vertiflex® Procedure (Superion® Indirect Decompression System) is a clinically proven, minimally invasive solution designed to deliver long-term relief for the pain associated with lumbar spinal stenosis (LSS).

Leading Radiofrequency Ablation.  We offer radiofrequency ablation (RFA) systems used by physicians to treat patients with chronic pain. RFA is a versatile outpatient procedure that is often used prior to SCS in the treatment continuum for chronic pain and has a more than 50-year track record of providing relief for patients with chronic pain. RFA is a minimally invasive, non-surgical, outpatient procedure that is often used prior to SCS in the treatment continuum for chronic pain and has a more than 50-year track record of providing relief for patients with chronic pain.


Conditions We Treat

  • Chronic Pain
  • Lumbar Spinal Stenosis
  • Parkinson’s Disease
  • Dystonia
  • Essential Tremor
  

Solutions We Offer

  • Rechargeable and Non-rechargeable Spinal Cord Stimulators
  • Indirect Decompression Systems
  • Radiofrequency Ablation Systems
  • Rechargeable and Non-rechargeable Deep Brain Stimulation Systems

Products:

Spectra WaveWriter™
Spectra WaveWriter™ is the only SCS system designed to engage multiple mechanisms simultaneously to deliver lasting relief to more patients.

 
therapy with mySCS
Boston Scientific can help you maximize your patients’ chances for successful therapy with mySCS™. This mobile app is designed to provide simple progress tracking during a Boston Scientific SCS trial, personalized goal setting, real-time support, and a summary report that patients can share with their physicians.

 
therapy with mySCS
The Vercise™ Primary Cell (PC) and Vercise Gevia™ Deep Brain Stimulation (DBS) Systems are engineered for precise neural targeting to customize therapy for patients with Parkinson’s disease. The rechargeable systems offer unique features including the longest battery life available for DBS therapy and the smallest footprint of any MICC stimulator available.ii
 

Sources

1 Nunley, et al. Clinical Interventions in Aging. 2017:12 1409 – 1717.

ii https://www.medtronic.com/us-en/healthcare-professionals/products/neurological/deep-brain-stimulation-systems/activa-rc.html | Accessed 08SEP2017

1. Bennett GJ. Neuropathic pain: an overview. In: Borsook D, ed. Progress in Pain Research and Management.Vol. 9. Seattle, Wa: IASP Press; 1997:109–113.

2. https://www.cdc.gov/features/arthritis-quality-life/index.html

3. https://www.apdaparkinson.org/article/parkinsons-disease-prevalence-study/

Top